Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than 10 million people worldwide. While current therapies address disease symptoms, they do not ...

New clinical data from the STEM-PD Phase I/II clinical trial have been presented at the ISSCR 2026 Annual Meeting. The study ...

An estimated 1.1 million Americans are living with Parkinson’s disease (PD), making it the second most common neurodegenerative disease after Alzheimer’s. “Parkinson’s is a disease in which neurons ...

Oral medications are often the first treatment for Parkinson’s disease. They work by increasing dopamine levels or mimicking dopamine’s effects, but symptom control may change over time. Infusion ...

Parkinson’s disease currently affects nearly one million Americans with no specific known cause and no cure. Treatments have come a long way over the past few decades focusing on managing symptoms and ...

CDC reports show Ohio's Parkinson's death rate among adults 65 and older was lower than Utah's 102.1 per 100,000 but remains ...

Dopamine agonists such as pramipexole, ropinirole, rotigotine, and apomorphine have long been recommended as initial therapy for younger patients with Parkinson’s disease, typically those younger than ...

New research presented today (Wednesday) at the Federation of European Neuroscience Societies (FENS) Forum 2026 has ...

New research presented at the Federation of European Neuroscience Societies (FENS) Forum 2026 has discovered some of the ...